Genenta Science (Nasdaq: Gnta)

Genenta Science (Nasdaq: Gnta) company information, Employees & Contact Information

Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Company Details

Employees
24
Founded
-
Address
Via Olgettina, 58, Milan,20132,italy
Email
in****@****nta.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Milan
Looking for a particular Genenta Science (Nasdaq: Gnta) employee's phone or email?

Genenta Science (Nasdaq: Gnta) Questions

News

Genenta Science Secures $15 Million Through American Depositary Shares Offering - Quiver Quantitative

Genenta Science Secures $15 Million Through American Depositary Shares Offering Quiver Quantitative

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production - Yahoo Finance

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production Yahoo Finance

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating (GNTA) - Seeking Alpha

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating (GNTA) Seeking Alpha

Genenta Science (Nasdaq: GNTA) prices $15M registered direct; 4,285,715 ADSs, no warrants - Stock Titan

Genenta Science (Nasdaq: GNTA) prices $15M registered direct; 4,285,715 ADSs, no warrants Stock Titan

Genenta Science Stock Skyrockets After Strategic Collaboration Announcement - StocksToTrade

Genenta Science Stock Skyrockets After Strategic Collaboration Announcement StocksToTrade

Why Is Genenta Science Stock (GNTA) Up 275% Today? - TipRanks

Why Is Genenta Science Stock (GNTA) Up 275% Today? TipRanks

Genenta Science and Anemocyte Collaboration Sends Shares Soaring - timothysykes.com

Genenta Science and Anemocyte Collaboration Sends Shares Soaring timothysykes.com

Why Is Genenta Science Stock Skyrocketing Friday? - Genenta Science (NASDAQ:GNTA) - Benzinga

Why Is Genenta Science Stock Skyrocketing Friday? - Genenta Science (NASDAQ:GNTA) Benzinga

Genenta Science Stock Ignites on Breakthrough Partnership That's Supercharging Biotech Innovation - RagingBull

Genenta Science Stock Ignites on Breakthrough Partnership That's Supercharging Biotech Innovation RagingBull

Genenta Science and Anemocyte Announce Expanded Collaboration on Advanced Therapy Solutions with Lentiviral Vector Technology - Quiver Quantitative

Genenta Science and Anemocyte Announce Expanded Collaboration on Advanced Therapy Solutions with Lentiviral Vector Technology Quiver Quantitative

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next? - ts2.tech

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next? ts2.tech

Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade

Genenta Science Soars Following Strategic Collaboration with Anemocyte StocksToTrade

Genenta (NASDAQ: GNTA) and Anemocyte broaden off-the-shelf LVV plasmid DNA for R&D to GMP - Stock Titan

Genenta (NASDAQ: GNTA) and Anemocyte broaden off-the-shelf LVV plasmid DNA for R&D to GMP Stock Titan

Genenta Science Reports Progress in Glioblastoma and Renal Cell Carcinoma Trials Involving Temferon - Nasdaq

Genenta Science Reports Progress in Glioblastoma and Renal Cell Carcinoma Trials Involving Temferon Nasdaq

Genenta Science Shares Experience Unprecedented 284% Surge Post Anemocyte Collaboration Announcement - timothysykes.com

Genenta Science Shares Experience Unprecedented 284% Surge Post Anemocyte Collaboration Announcement timothysykes.com

Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail

Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO The Globe and Mail

Why Genenta Science S.p.A. Depositary Receipt stock is considered a top pick - 2025 Dividend Review & Weekly Setup with High ROI Potential - Trung tâm Dự báo KTTV quốc gia

Why Genenta Science S.p.A. Depositary Receipt stock is considered a top pick - 2025 Dividend Review & Weekly Setup with High ROI Potential Trung tâm Dự báo KTTV quốc gia

Genenta Science Leads The Charge With 2 Other Promising Penny Stocks - Yahoo Finance

Genenta Science Leads The Charge With 2 Other Promising Penny Stocks Yahoo Finance

Published on: 2025-10-18 06:56:34 - Trung tâm Dự báo KTTV quốc gia

Published on: 2025-10-18 06:56:34 Trung tâm Dự báo KTTV quốc gia

Temferon Linked to Long-Term Survival in Some With Glioblastoma - CUREtoday.com

Temferon Linked to Long-Term Survival in Some With Glioblastoma CUREtoday.com

Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025? - Yahoo Finance

Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025? Yahoo Finance

Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism - Yahoo Finance

Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism Yahoo Finance

Genenta Science stock plunges after $15 million ADS offering - Investing.com

Genenta Science stock plunges after $15 million ADS offering Investing.com

Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech - Investing.com

Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech Investing.com

Genenta Science Secures $15 Million in Registered Direct Offering - TipRanks

Genenta Science Secures $15 Million in Registered Direct Offering TipRanks

Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 - TipRanks

Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 TipRanks

February 2025 US Penny Stocks With Promising Prospects - simplywall.st

February 2025 US Penny Stocks With Promising Prospects simplywall.st

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth? - Yahoo Finance

Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth? Yahoo Finance

Genenta Science And 2 Other Penny Stocks To Consider - simplywall.st

Genenta Science And 2 Other Penny Stocks To Consider simplywall.st

Risk Report: Why Genenta Science S.p.A. Depositary Receipt stock is considered a top pick - 2025 Technical Patterns & Fast Gain Swing Trade Alerts - Trung tâm Dự báo KTTV quốc gia

Risk Report: Why Genenta Science S.p.A. Depositary Receipt stock is considered a top pick - 2025 Technical Patterns & Fast Gain Swing Trade Alerts Trung tâm Dự báo KTTV quốc gia

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings - Benzinga

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings Benzinga

GNTA - Genenta Science Spa Latest Stock News & Market Updates - Stock Titan

GNTA - Genenta Science Spa Latest Stock News & Market Updates Stock Titan

Earnings Update: Can Genenta Science S.p.A. Depositary Receipt stock deliver surprise earnings beat - 2025 Dividend Review & Technical Entry and Exit Tips - Trung tâm Dự báo KTTV quốc gia

Earnings Update: Can Genenta Science S.p.A. Depositary Receipt stock deliver surprise earnings beat - 2025 Dividend Review & Technical Entry and Exit Tips Trung tâm Dự báo KTTV quốc gia

How Genenta Science S.p.A. Depositary Receipt stock benefits from tech adoption - Market Activity Report & Capital Protection Trade Alerts - Trung tâm Dự báo KTTV quốc gia

How Genenta Science S.p.A. Depositary Receipt stock benefits from tech adoption - Market Activity Report & Capital Protection Trade Alerts Trung tâm Dự báo KTTV quốc gia

H.C. Wainwright Maintains Genenta Science(GNTA.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

H.C. Wainwright Maintains Genenta Science(GNTA.US) With Buy Rating, Maintains Target Price $25 富途牛牛

Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com South Africa

Genenta Science stock plunges after $15 million ADS offering By Investing.com Investing.com South Africa

Genenta Science stock soars on strategic LVV Plasmid DNA collaboration By Investing.com - Investing.com Nigeria

Genenta Science stock soars on strategic LVV Plasmid DNA collaboration By Investing.com Investing.com Nigeria

Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com Australia

Genenta Science stock plunges after $15 million ADS offering By Investing.com Investing.com Australia

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme - OncLive

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme OncLive

Genenta sells ADS shares worth $15 million - Startupbusiness.it

Genenta sells ADS shares worth $15 million Startupbusiness.it

Genenta Science stock tumbles as $15 million ADS sale sparks dilution worries - MSN

Genenta Science stock tumbles as $15 million ADS sale sparks dilution worries MSN

Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com Philippines

Genenta Science stock plunges after $15 million ADS offering By Investing.com Investing.com Philippines

Samsara, Genenta Science Had Their IPOs. Here's How They Did. - Barron's

Samsara, Genenta Science Had Their IPOs. Here's How They Did. Barron's

Italy’s private equity weekly roundup. News from Zegna, Genenta Science, Reno de’ Medici, FiberCop, Open Fiber, Pegasus, Conbipel and more – BeBeez International - BeBeez International

Italy’s private equity weekly roundup. News from Zegna, Genenta Science, Reno de’ Medici, FiberCop, Open Fiber, Pegasus, Conbipel and more – BeBeez International BeBeez International

Italy’s biotech company Genenta Science strikes a new 13.2 mln euros round led by Chinese private equity firm Qianzhan and Fidim, the holding company of the Rovati family – BeBeez International - BeBeez International

Italy’s biotech company Genenta Science strikes a new 13.2 mln euros round led by Chinese private equity firm Qianzhan and Fidim, the holding company of the Rovati family – BeBeez International BeBeez International

Ex-GSK rare disease head moves to Genenta - Fierce Biotech

Ex-GSK rare disease head moves to Genenta Fierce Biotech

Genenta cashes in 7 mln euros in a Series B investment round, reaching 17 mln euros in total capital raised - BeBeez International

Genenta cashes in 7 mln euros in a Series B investment round, reaching 17 mln euros in total capital raised BeBeez International

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - 24matins.uk

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares 24matins.uk

Genenta Extends Collaboration With Anemocyte To Boost Off-The-Shelf Genetic Therapy Production - NewsBreak: Local News & Alerts

Genenta Extends Collaboration With Anemocyte To Boost Off-The-Shelf Genetic Therapy Production NewsBreak: Local News & Alerts

Top Genenta Science (Nasdaq: Gnta) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant